BIIB Q3 2025 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena

BIIBBiogen Inc.

$28B

Q3 2025 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$2.5B-0.4% YoY

Gross Profit

$1.6B64.3% margin

Operating Income

$614M25.0% margin

Net Income

$467M19.0% margin

EPS (Diluted)

$3.17

QoQ Revenue Growth

-7.2%

Cash Flow

Operating Cash Flow

$1.3B

Free Cash Flow

$1.2B

Stock-Based Comp.

$75M

Balance Sheet

Total Assets

$29.2B

Total Liabilities

$11.0B

Stockholders' Equity

$18.2B

Cash & Equivalents

$3.9B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.5B	$2.5B	-0.4%
Gross Profit	$1.6B	$1.8B	-13.6%
Operating Income	$614M	$577M	+6.3%
Net Income	$467M	$389M	+20.1%

Revenue Segments

MS Product Revenues

$1.1B43%

TYSABRI product

$432M17%

Fumarate

$383M15%

SPINRAZA

$374M15%

Interferon

$247M10%

Geographic Segments

UNITED STATES

$935M51%

Non-US

$912M49%